Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Symptomatic Neurogenic Orthostatic Hypotension”

13 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 13 of 13 results

Large-scale testing (Phase 3)Study completedNCT03750552
What this trial is testing

Clinical Effect of Ampreloxetine (TD-9855) for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure

Who this might be right for
Symptomatic Neurogenic Orthostatic Hypotension
Theravance Biopharma 195
Early research (Phase 1)Study completedNCT01149629
What this trial is testing

Study of the Fed-Fast Pharmocokinetics and Bioequivalance of 300mg Capsules of Droxidopa

Who this might be right for
Symptomatic Neurogenic Orthostatic Hypotension
Chelsea Therapeutics 24
Large-scale testing (Phase 3)Study completedNCT00633880
What this trial is testing

Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH)

Who this might be right for
Symptomatic Neurogenic Orthostatic Hypotension (NOH)Non-diabetic NeuropathyPrimary Autonomic Failure+1 more
Chelsea Therapeutics 181
Large-scale testing (Phase 3)Study completedNCT01132326
What this trial is testing

Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH) (Droxi-304)

Who this might be right for
Primary Autonomic FailureDopamine Beta Hydroxylase DeficiencyNon-Diabetic Neuropathy+1 more
Chelsea Therapeutics 350
Large-scale testing (Phase 3)Study completedNCT00782340
What this trial is testing

A Clinical Study for Patients With Neurogenic Orthostatic Hypotension (NOH) Using Droxidopa

Who this might be right for
Symptomatic Neurogenic Orthostatic Hypotension (NOH)Non-diabetic NeuropathyPrimary Autonomic Failure+1 more
Chelsea Therapeutics 263
Large-scale testing (Phase 3)Study completedNCT01176240
What this trial is testing

A Two Part Study (306A/306B) to Assess Droxidopa in Treatment of NOH in Patients With Parkinson's Disease

Who this might be right for
Orthostatic HypotensionParkinson's Disease
Chelsea Therapeutics 225
Large-scale testing (Phase 3)Study completedNCT00738062
What this trial is testing

Open-Label Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH)

Who this might be right for
Neurogenic Orthostatic HypotensionNon-Diabetic Autonomic NeuropathyMultiple System Atrophy+1 more
Chelsea Therapeutics 103
Large-scale testing (Phase 3)Ended earlyNCT01927055
What this trial is testing

A Clinical Study of Patients With Symptomatic NOH to Assess Sustained Effects of Droxidopa Therapy

Who this might be right for
Symptomatic Neurogenic Orthostatic HypotensionParkinson's DiseaseMultiple Systems Atrophy+2 more
Chelsea Therapeutics 61
Post-approval studies (Phase 4)Study completedNCT02586623
What this trial is testing

Sustained Effect of Droxidopa in Symptomatic Neurogenic Orthostatic Hypotension

Who this might be right for
Symptomatic Neurogenic Orthostatic Hypotension
H. Lundbeck A/S 453
Testing effectiveness (Phase 2)UnknownNCT00758849
What this trial is testing

Fipamezole in Neurogenic Orthostatic Hypotension

Who this might be right for
Symptomatic Neurogenic Orthostatic Hypotension (NOH)Parkinson's DiseaseMultiple System Atrophy
Juvantia Pharma Ltd 24
Large-scale testing (Phase 3)Ended earlyNCT03829657
What this trial is testing

Phase 3 Clinical Effect Durability of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure

Who this might be right for
Symptomatic Neurogenic Orthostatic HypotensionMSAParkinson's Disease (PD)+1 more
Theravance Biopharma 203
Large-scale testing (Phase 3)Active Not RecruitingNCT05696717
What this trial is testing

Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy

Who this might be right for
Symptomatic Neurogenic Orthostatic HypotensionMSA - Multiple System Atrophy
Theravance Biopharma 102
Large-scale testing (Phase 3)Ended earlyNCT04095793
What this trial is testing

Phase 3 Open-Label Extension Study of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure

Who this might be right for
Symptomatic Neurogenic Orthostatic Hypotension
Theravance Biopharma 110